Fred Ramsdell, Ph.D.


Fred Ramsdell is advising Equilium on its core immunology programs. Fred is Vice President of Research at the Parker Institute for Cancer Immunology, where he leads the development of collaborative research programs. Prior to joining the Parker Institute, Fred served as vice president at aTyr Pharma, helped establish Novo Nordisk’s Inflammation Research Center in Seattle and led immunobiology discovery efforts at ZymoGenetics and Darwin Molecular/Celltech Pharma.

Fred earned his doctoral degree in microbiology and immunology from the University of California, Los Angeles and holds a Bachelor’s degree in Biochemistry and Cell biology from the University of California, San Diego. After a fellowship at the National Institutes of Health, Fred joined Immunex, studying T-cell activation and tolerance, including the identification and characterization of various tumor necrosis factors and their receptors. He later joined Darwin Molecular, which was acquired by Celltech, to establish their immunology program. His work there included important discoveries about regulatory T-cells that counteract harmful immune reactions in arthritis and other autoimmune diseases. He demonstrated that mutation in the gene now known as FOXP3, which is vital to regulatory T-cells, causes the severe congenital disease IPEX. The Royal Swedish Academy of Sciences honored Fred and two other scientists with the Crafoord Prize for their pioneering work related to regulatory T-cells and the role of the FOXP3 gene.